Cargando…
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials
Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium-glucose cotransporter-2) inhibitors on these outcomes vary across the full range of EF remains unclear. METHODS: Patient-level data we...
Autores principales: | Nassif, Michael E., Windsor, Sheryl L., Gosch, Kensey, Borlaug, Barry A., Husain, Mansoor, Inzucchi, Silvio E., Kitzman, Dalane W., McGuire, Darren K., Pitt, Bertram, Scirica, Benjamin M., Shah, Sanjiv J., Umpierrez, Guillermo, Austin, Bethany A., Lamba, Sumant, Khumri, Taiyeb, Sharma, Kavita, Kosiborod, Mikhail N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348645/ https://www.ncbi.nlm.nih.gov/pubmed/37203441 http://dx.doi.org/10.1161/CIRCHEARTFAILURE.122.009837 |
Ejemplares similares
-
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023) -
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021) -
Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020) -
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
por: Curtain, James P, et al.
Publicado: (2021) -
Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)